Semaglutide Withdrawal Raises Insulin Needs, Weight Regain in Type 1 Diabetes
The abrupt cessation of semaglutide, commonly known as Ozempic, leads to a swift increase in insulin requirements for individuals with type 1 diabetes, a recent analysis reveals. The findings, presented at the International Conference on Advanced Technologies & Treatments for Diabetes in March 2026, underscore the physiological response when the medication is discontinued and highlight the need for careful monitoring and insulin adjustments.
Researchers assessed data from 11 adults with type 1 diabetes who initially received semaglutide and then transitioned to a placebo as part of a randomized, double-blind crossover trial. The analysis focused on changes in daily insulin dosage and carbohydrate intake following semaglutide withdrawal. The study, led by Melissa-Rosina Pasqua, MD, PhD, of the McGill University Health Centre in Canada, found that participants experienced a near-return to baseline insulin levels within three weeks of stopping semaglutide. Bolus insulin doses, specifically, increased significantly by day 35 of withdrawal.
Semaglutide’s Impact on Insulin Needs
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in improving glucose control and reducing insulin requirements in individuals with type 1 diabetes when used in conjunction with hybrid closed-loop insulin delivery systems. Previous research demonstrated that adding semaglutide to a hybrid closed-loop system resulted in higher time in range and a decrease in total daily insulin dose compared to placebo. However, this latest analysis sheds light on what happens when the medication is stopped.
The study participants experienced a median weight regain of 4.1 kg after discontinuing semaglutide, further indicating a metabolic shift. While daily basal insulin doses remained relatively stable throughout the trial, the need for bolus insulin – the dose taken to cover carbohydrate intake – increased notably after semaglutide withdrawal. This suggests that the medication’s effect on post-meal glucose control is significant, and its absence requires a corresponding adjustment in insulin therapy.
Carbohydrate Intake and Time in Range
Interestingly, the analysis also revealed changes in carbohydrate consumption. While carbohydrate intake remained relatively consistent during semaglutide therapy, it increased significantly 11 weeks after discontinuation. Dr. Pasqua noted that variations in carbohydrate input between participants were considerable, and cautioned that “phantom carbing” – a phenomenon where insulin pumps inaccurately register carbohydrate intake – could be a confounding factor, particularly with older generation pump algorithms.
Time in range, a measure of how often blood glucose levels remain within a target range, was highest during semaglutide therapy and declined after withdrawal, before beginning to increase again between weeks three and five. This fluctuation underscores the dynamic interplay between medication, insulin dosage, and glucose control.
Clinical Implications and Insulin Adjustments
The findings have significant implications for clinical practice. Over half of the participants (53%) required an increase in their insulin dose during follow-up visits after stopping semaglutide, while 25% experienced a dose reduction and 23% had mixed changes. Insulin-to-carbohydrate ratios were decreased in 75% of follow-up visits, indicating a need for more insulin per gram of carbohydrate consumed.
The study highlights the importance of close monitoring and individualized insulin adjustments when discontinuing semaglutide in individuals with type 1 diabetes. Healthcare providers should be prepared to address a potential increase in insulin requirements and counsel patients on the importance of careful blood glucose monitoring and carbohydrate counting.
Study Limitations and Future Research
It’s important to acknowledge the limitations of this post hoc analysis. The relatively small sample size (11 participants) limits the generalizability of the findings. The use of various insulin pump models, some with older algorithms prone to inaccuracies, could have introduced confounding factors. Two participants withdrew from the trial after three weeks in the placebo arm, both expressing a desire to resume semaglutide due to its positive effects on glucose control and well-being.
Dr. Pasqua emphasized the need for future studies to explicitly disclose the potential for decreased time in range and increased insulin needs following semaglutide withdrawal. Further research is also warranted to investigate the optimal strategies for managing insulin therapy during and after semaglutide discontinuation. Smart insulin pens and continuous glucose monitoring systems may play a role in facilitating more precise insulin adjustments in these situations.
Guidance on Insulin Injection Technique
Maintaining proper insulin injection technique is crucial for effective glucose control, particularly when insulin dosages are being adjusted. Updated recommendations from an international group of diabetes experts, detailed in guidance released in April 2025, emphasize the importance of appropriate needle size and injection angle. These guidelines aim to inform diabetes educators and ensure that individuals are administering insulin correctly.
As the landscape of diabetes management continues to evolve with the introduction of new medications like semaglutide, ongoing research and careful clinical monitoring are essential to optimize patient care and ensure safe and effective treatment strategies. The findings from this analysis serve as a valuable reminder of the complex interplay between medications, insulin therapy, and glucose control in individuals with type 1 diabetes.